Abstract
Abstract Extreme drug resistant (XDR) Acinetobacter baumannii is a rapidly emerging pathogen causing infections with unacceptably high mortality rates due to inadequate available treatment. Prevention of such infections is a critical unmet medical need. Because diabetes is a clinical risk factor for A. baumannii infections, a diabetes ketoacidosis (DKA) mouse model of such infections was established to support a rational vaccine discovery program. Specific humoral immune responses to A. baumannii cell membrane proteins occurred during tail-vein infection with multiple clinical isolates in DKA mice. Western blots with paired pre-immune and immune sera identified outer membrane protein A (OmpA) as the immunodominant antigen. Vaccination of DKA mice with recombinant OmpA (rOmpA) with aluminum hydroxide adjuvant markedly improved survival, reduced tissue bacterial burden, and promoted inflammatory cytokine production in infected tissues. rOmpA is a promising vaccine candidate to prevent A. baumannii infections.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
